by Precedence Research a new report on cardiovascular drugs market size, share, growth, industry trends, and forecast 2030, covering various industry elements and growth trends helpful for predicting the market’s future. The global cardiovascular drugs market size was valued at US$ 155.6 billion in 2021. The global cardiovascular drugs market is projected to reach US$ 231.7 billion by 2030, registering a compound annual growth rate (CAGR) of 4.52% during the forecast period from 2022 to 2030.
Download Free Sample Copy with TOC@ https://www.precedenceresearch.com/sample/2037
The global cardiovascular drugs market report offers various segments analysis by size, trends, growth factors, opportunities and key country outlook to 2030. The report offers a detailed analysis and information as per cardiovascular drugs, market segments helping our readers to get a comprehensive overview of the global market. Several players are planning to focus on developing cost-effective products or services, aiming to maintain a strong foothold in the market.
Cardiovascular Drugs Market Report Scope
| Report Coverage | Details |
| Market Size in 2022 | USD 162.64 Billion |
| Market Size by 2030 | USD 231.7 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 4.52% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Drug Type, Disease Indication, Route of Administration, Drug, Mode of Purchase, End Users, Geography |
The company profiling of leading market players is included this report with Porter’s five forces analysis and Value Chain analysis. Further, the strategies exercised by the companies for expansion of business through mergers, acquisitions, and other business development measures are discussed in the report. The financial parameters which are assessed include the sales, profits and the overall revenue generated by the key players of Market.
Read Also@ Cardiovascular Ultrasound Market Size to Hit Around US$ 2.7 billion by 2030
Some of the prominent players in the cardiovascular drugs market include:
- Bristol-Myers Squibb Company
- Bayer AG
- Pfizer Inc.
- Janssen Pharmaceuticals, Inc.
- Novartis AG
- Merck & Co.
- AstraZeneca
- Sanofi
- Gilead Sciences, Inc.
- F. Hoffmann-La Roche
Cardiovascular Drugs Market Segmentation
By Drug Type
- Antihypertensive
- Anticoagulants
- Antihyperlipidemic
- Antiplatelet Drugs
- Others
By Disease Indication
- Hypertension
- Coronary Artery Disease
- Hyperlipidaemia
- Arrhythmia
- Others
By Route of Administration
- Oral
- Parenteral
- Others
By Drug Classification
- Branded Drugs
- Generic Drugs
By Mode of Purchase
- Prescription-Based Drugs
- Over-The-Counter Drugs
By End Users
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Others
Regional Segmentation
- Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
- Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
- North America [United States, Canada, Mexico]
- South America [Brazil, Argentina, Columbia, Chile, Peru]
- Middle East & Africa [GCC, North Africa, South Africa]
Key Questions are
- What are the key factors influencing the cardiovascular drugs market in each region?
- How much value will the global market generate by the end of the forecast period?
- What will be the CAGR of the global market between 2022 and 2030?
- What would be the Y-o-Y growth trend of the global market between 2022 and 2030?
- What is the future scope and current trends in technologies of the global market?
- What is the revenue of the global market based on segments?
- Which key strategies are used by top players of the global market?
- Which are the leading companies in the global market?
- What are the essential strategies by key stakeholders in the market to expand their geographic presence?
- What are the major advancements witnessed in the global market?
Research Objectives and Research Approach
The comprehensive report on the global cardiovascular drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products. Following this, the report provides detailed explanation of objectives of this study and laid down by accredited agencies in the purview of research in the global cardiovascular drugs market.
It is followed by market introduction, market dynamics, and an overview of the global market, which includes analysis of market drivers, restraints, and trends pertaining to the global market. Furthermore, Y-o-Y growth analysis with elaborated insights has been provided in order to understand the Y-o-Y growth trend of the global market.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global cardiovascular drugs market in terms of type, application, region and others. Key segments under each criteria are studied at length, and the market share for each of these at the end of 2030 has also been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global market.
Why should you invest in this report?
If you are aiming to enter the global cardiovascular drugs market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for cardiovascular drugs are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. End Users Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cardiovascular Drugs Market
5.1. COVID-19 Landscape: Cardiovascular Drugs Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cardiovascular Drugs Market, By Drug Type
8.1. Cardiovascular Drugs Market, by Drug Type, 2022-2030
8.1.1. Antihypertensive
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Anticoagulants
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Antihyperlipidemic
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Antiplatelet Drugs
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Cardiovascular Drugs Market, By Disease Indication
9.1. Cardiovascular Drugs Market, by Disease Indication, 2022-2030
9.1.1. Hypertension
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Coronary Artery Disease
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Hyperlipidaemia
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Arrhythmia
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Cardiovascular Drugs Market, By Route of Administration
10.1. Cardiovascular Drugs Market, by Route of Administration, 2022-2030
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Parenteral
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Cardiovascular Drugs Market, By Drug Classification
11.1. Cardiovascular Drugs Market, by Drug Classification, 2022-2030
11.1.1. Branded Drugs
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Generic Drugs
11.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Cardiovascular Drugs Market, By Mode of Purchase
12.1. Cardiovascular Drugs Market, by Mode of Purchase, 2022-2030
12.1.1. Prescription-Based Drugs
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Over-The-Counter Drugs
12.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Cardiovascular Drugs Market, By End Users
13.1. Cardiovascular Drugs Market, by End Users, 2022-2030
13.1.1. Hospital Pharmacies
13.1.1.1. Market Revenue and Forecast (2017-2030)
13.1.2. Online Pharmacies
13.1.2.1. Market Revenue and Forecast (2017-2030)
13.1.3. Retail Pharmacies
13.1.3.1. Market Revenue and Forecast (2017-2030)
13.1.4. Others
13.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 14. Global Cardiovascular Drugs Market, Regional Estimates and Trend Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.1.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.1.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.1.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.1.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.1.6. Market Revenue and Forecast, by End Users (2017-2030)
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.1.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.1.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.1.7.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.1.8. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.1.8.1. Market Revenue and Forecast, by End Users (2017-2030)
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.1.9.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.1.9.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.1.9.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.1.10. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.1.11. Market Revenue and Forecast, by End Users (2017-2030)
14.1.11.1.
14.2. Europe
14.2.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.2.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.6. Market Revenue and Forecast, by End Users (2017-2030)
14.2.7.
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.8.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.2.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.9. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2.10. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.10.1. Market Revenue and Forecast, by End Users (2017-2030)
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.11.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.2.11.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.12. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2.13. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.14. Market Revenue and Forecast, by End Users (2017-2030)
14.2.14.1.
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.15.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.2.15.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.15.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2.16. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.16.1. Market Revenue and Forecast, by End Users (2017-2030)
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.17.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.2.17.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.17.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2.18. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.18.1. Market Revenue and Forecast, by End Users (2017-2030)
14.3. APAC
14.3.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.3.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.6. Market Revenue and Forecast, by End Users (2017-2030)
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.3.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.7.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3.8. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.9. Market Revenue and Forecast, by End Users (2017-2030)
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.10.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.3.10.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.10.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3.11. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.11.1. Market Revenue and Forecast, by End Users (2017-2030)
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.12.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.3.12.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.12.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3.12.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.12.6. Market Revenue and Forecast, by End Users (2017-2030)
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.13.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.3.13.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.13.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3.13.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.13.6. Market Revenue and Forecast, by End Users (2017-2030)
14.4. MEA
14.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.6. Market Revenue and Forecast, by End Users (2017-2030)
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.4.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.7.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4.8. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.9. Market Revenue and Forecast, by End Users (2017-2030)
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.10.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.4.10.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.10.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4.11. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.12. Market Revenue and Forecast, by End Users (2017-2030)
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.13.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.4.13.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.13.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4.13.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.13.6. Market Revenue and Forecast, by End Users (2017-2030)
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.14.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.4.14.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.14.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4.14.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.14.6. Market Revenue and Forecast, by End Users (2017-2030)
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.5.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.5.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.5.6. Market Revenue and Forecast, by End Users (2017-2030)
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.5.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.5.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.5.7.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.5.8. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.5.8.1. Market Revenue and Forecast, by End Users (2017-2030)
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.5.9.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.5.9.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.5.9.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.5.9.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.5.9.6. Market Revenue and Forecast, by End Users (2017-2030)
Chapter 15. Company Profiles
15.1. Bristol-Myers Squibb Company
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Bayer AG
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Pfizer Inc
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Janssen Pharmaceuticals, Inc.
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Novartis AG
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Merck & Co.
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. AstraZeneca
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Sanofi
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Gilead Sciences, Inc
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. F. Hoffmann-La Roche
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
Chapter 16. Research Methodology
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
Chapter 17. Appendix
17.1. About Us
17.2. Glossary of Terms
Buy This Premium Research Report Click Here@ https://www.precedenceresearch.com/checkout/2037
Our Press Release@ https://www.precedenceresearch.com/press-releases
About Us
Precedence Research is a Canada/India based company and one of the leading providers of strategic market insights. We offer executive-level blueprints of markets and solutions beyond flagship surveys. Our repository covers consultation, syndicated market studies, and customized research reports. Through our services we aim at connecting an organization’s goal with lucrative prospects globally.
From gauging investment feasibility to uncovering hidden growth opportunities, our market studies cover in-depth analysis, which also is interspersed with relevant statistics. Recommendation are often enclosed within our reports with the sole intent of enabling organizations achieve mission-critical success.
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
